AJCP / Meeting AbstrActs had positive ELISA test results , and no patients with a pretest probability of ≤2 had positive HIT ELISA test results. Conclusion: These data suggest that HIT can be ruled out with a negative predictive value of 100% (95% CI 0.75-1.0) and a sensitivity of 100% (95% CI 0.95-1.0) in cancer patients when low probability for HIT is defined by a 4Ts score of 0-2. Using this modified score, laboratory testing could be eliminated in 47.9% (67/140) of the study cohort with substantial conservation of clinical and laboratory resources. 
interfering substances were identified, and no carryover was observed immediately after a sample containing 60 ng/g. The recovery observed for the four analytes was 55% ± 20%. Regarding the method comparison, the majority of results from LC-MS/MS were consistent with the findings from ELISA. For high positive specimens, 55% specimens (n = 4) were positive for all four analytes, with THCA exhibiting the highest concentrations (1.5-11.3 ng/g); for positive specimens, 20% of specimens (n = 2) were positive for all four analytes and, similarly, THCA showed the highest concentrations ranging from 0.6 ng/g to 9.5 ng/g. For low positive specimens, we found that concentrations of THCA were slightly lower than those in high positive and positive specimens (0.8 ng/g to 6.5 ng/g). Four out of ten indeterminate specimens were positive for at least one analyte. We also found that two out of seven specimens negative by ELISA were positive by LC-MS/MS for CBN with concentrations of 78.4 pg/g and 76.5 pg/g, respectively. Conclusion: The presented method was acceptable for the assessment of in utero marijuana exposure providing quantitative results for four marijuana metabolites.
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Institutional Adherence to CDC Guidelines for Hepatitis C Virus Screening Reveals Added Utility of Confirmatory Molecular Testing
Paul Lee, Satoru Kudose, Ronald Jackups, Neil Anderson;Washington University, St Louis, MO Introduction: Current Centers for Disease Control and Prevention (CDC) recommendations for hepatitis C virus (HCV) screening include confirmation of reactive HCV antibody (HCVAB) results for all patients and confirmation of nonreactive results for patients who may have been exposed within the past six months. Our aim was to assess adherence to these recommendations at a 1,250-bed tertiary care hospital in the Midwestern United States. In cases for which confirmatory testing was performed, our secondary aim was to determine the accuracy of the HCVAB screen for the assessment of active HCV infection. Methods: We retrospectively identified consecutive HCVAB samples tested by the ADVIA Centaur Immunoassay System over a period of seven years (January 2010 to December 2016) and by the COBAS AmpliPrep/COBAS TaqMan HCV RNA viral load assay (HCVRNA) over the same time period. The HCVAB test results were recorded as well as the percentage of reactive and nonreactive results that received confirmatory testing within 30 days. When both tests were performed, we calculated the concordance rates. Using the HCVRNA as the gold standard, we calculated the positive predictive values (PPVs) and negative predictive values (NPVs) of the HCVAB for the detection of active HCV disease within the patient population receiving both tests within 30 days of each other and within the patient population receiving both tests within one day of each other. The technological revolution has changed the field of laboratory medicine with a shift from manual specimen processing to automation. Many laboratories have transitioned to robotic processing for high throughput testing in an effort to enhance workflow, improve efficiency, decrease turnaround time (TAT), and maximize resource utilization. This is beneficial for patient care and client satisfaction, and advantageous in a field of diminishing resources and skilled personnel shortages. This study analyzed the TAT for troponin testing before and after implementation of an automated laboratory at an academic medical center. Data collected included the monthly troponin TAT (reported as the time interval that 90% of samples are complete from receipt in lab to result time), and the number of troponin tests performed by the laboratory from 2015 to 2016. The medical center transitioned from Abbott ARCHITECT (i2000 SR , i1000 SR ) analyzers (North Chicago, IL) manually loaded and operated by medical technologists to the Roche cobas 8000 modular analyzer series with a modular preanalytic (MPA) system in November 2015. The MPA scans the specimen barcodes, downloads the assay requests, centrifuges the samples, aliquots them (if necessary), and triages to the appropriate analyzer using a robotic track. The TAT increased from 43.3 minutes in October 2015 (preautomation) to 113.3 minutes in November 2015 (postautomation), peaking in January 2016 at 147.5 minutes. The TAT remained above 100 minutes until a system change was implemented at the end of June 2016. The overall troponin test volume did not increase after implementation of the automated laboratory. The increase in TAT was caused by an inability to triage troponin specimens prior to being placed on the MPA and a longer than expected wait time for centrifugation once loaded on the MPA. The troponin assay and many other assays were performed using serum separator tubes, and the new system allowed multiple assays to share a tube. Therefore, no visual triage was possible for specimens with a troponin order; hence, these specimens were not preferentially loaded onto the MPA. While the troponin assay was the first test performed if other assays shared the tube, the time spent in queue was a significant delay factor. To mitigate the problem, the specimen tube for the troponin assay was changed from a serum separator tube to a designated lithium heparin tube (green top) that was only used for troponin assays. The green top was a visual signal for immediate loading onto the MPA. This helped decrease the TAT to 70.5 minutes the month after implementation with a continued downward trend to a nadir of 67.3 minutes in December 2016. The laboratory is considering the purchase of additional instrumentation to decrease TAT further. This study describes an unexpected pitfall of automation and highlights the importance of a thorough workflow assessment.
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Validation of a Multi-Wavelength Spectrophotometric Assay for Detection of Xanthochromia in Suspected Subarachnoid Hemorrhage
Paula Jenkins Colon, Geoffrey Baird;University of Washington, Seattle
Subarachnoid hemorrhage (SAH) is a catastrophic neurologic event with significant morbidity and mortality. Timely diagnosis is associated with improved outcomes. Computed tomography (CT) is the initial diagnostic procedure with sensitivity of 95% if performed within 12 hours, but sensitivity rapidly decreases and approaches 50% by one week. A more sensitive test during this interval could identify patients who would most benefit most from early intervention. Evaluation of cerebral spinal fluid
